Inotuzumab ozogamicin is an effective treatment for CD22-positive acute undifferentiated leukemia: A case report
Running title: Inotuzumab ozogamicin for CD22-positive AUL
Ryo Akazawa,1 Itaru Kato,1 Hirohito Kubota,1 Kiyotaka Isobe,1 Hiroaki Masuno,2 Masamitsu Mikami,2Mitsutaka Shiota,2 Kagehiro Kohzuki,1 Naoko Kawabata,1 Kuniaki Tanaka,1 Satoshi Saida,1 Katsutsugu Umeda,1 Hidefumi Hiramatsu,1 Souichi Adachi,3 and Junko Takita1
1Department of Pediatrics Graduate School of Medicine, Kyoto University
2Department of Pediatrics, Kitano Hospital, The Tazuke Kofukai, Medical Research Institute
3Department of Human Health Sciences, Graduate School of Medicine, Kyoto University
Corresponding author: Itaru Kato
Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
Phone: +81-75-751-3290; Fax: +81-75-752-2361
E-mail address: itarkt@kuhp.kyoto-u.ac.jp
Text word count: abstract, 95 words; main text, 1,104 words
Number of tables and figures: 0 tables; 2 figures